Chronic verapamil administration alters phenytoin pharmacokinetics in the rat

M. O M Tanira; I. A. Wasfi; A. K. Bashir; D. W G Harron

doi:10.1016/0378-5173(94)90065-5

Chronic verapamil administration alters phenytoin pharmacokinetics in the rat

M. O M Tanira, I. A. Wasfi, A. K. Bashir, D. W G Harron

Pharmacology & Clinical Pharmacy

Research output: Contribution to journal › Article

Abstract

The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61%; p < 0.01 and 80%; p < 0.05), the area under the plasma concentration curve (32% n.s. and 48; p < 0.05) and volume of distribution (17%; p < 0.05 and 14% n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75% (n.s.) and 67% (p < 0.05) of the control value; changes were not dose-dependent.

Original language	English
Pages (from-to)	267-269
Number of pages	3
Journal	International Journal of Pharmaceutics
Volume	102
Issue number	1-3
DOIs	https://doi.org/10.1016/0378-5173(94)90065-5
Publication status	Published - Feb 7 1994

Fingerprint

Keywords

Pharmacokinetics
Phenytoin
Rat
Verapamil

ASJC Scopus subject areas

Pharmaceutical Science

Cite this

Tanira, M. O. M., Wasfi, I. A., Bashir, A. K., & Harron, D. W. G. (1994). Chronic verapamil administration alters phenytoin pharmacokinetics in the rat. International Journal of Pharmaceutics, 102(1-3), 267-269. https://doi.org/10.1016/0378-5173(94)90065-5

@article{937450680084422fb7a059914f097316,

title = "Chronic verapamil administration alters phenytoin pharmacokinetics in the rat",

abstract = "The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61{\%}; p < 0.01 and 80{\%}; p < 0.05), the area under the plasma concentration curve (32{\%} n.s. and 48; p < 0.05) and volume of distribution (17{\%}; p < 0.05 and 14{\%} n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75{\%} (n.s.) and 67{\%} (p < 0.05) of the control value; changes were not dose-dependent.",

keywords = "Pharmacokinetics, Phenytoin, Rat, Verapamil",

author = "Tanira, {M. O M} and Wasfi, {I. A.} and Bashir, {A. K.} and Harron, {D. W G}",

year = "1994",

month = "2",

day = "7",

doi = "10.1016/0378-5173(94)90065-5",

language = "English",

volume = "102",

pages = "267--269",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - Chronic verapamil administration alters phenytoin pharmacokinetics in the rat

AU - Tanira, M. O M

AU - Wasfi, I. A.

AU - Bashir, A. K.

AU - Harron, D. W G

PY - 1994/2/7

Y1 - 1994/2/7

N2 - The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61%; p < 0.01 and 80%; p < 0.05), the area under the plasma concentration curve (32% n.s. and 48; p < 0.05) and volume of distribution (17%; p < 0.05 and 14% n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75% (n.s.) and 67% (p < 0.05) of the control value; changes were not dose-dependent.

AB - The interaction of verapamil (4 and 8 mg/kg twice daily for 7 days) and i.v. phenytoin (10 mg/kg) in male Wistar rats has been studied. Increases occurred in phenytoin plasma elimination half-life (61%; p < 0.01 and 80%; p < 0.05), the area under the plasma concentration curve (32% n.s. and 48; p < 0.05) and volume of distribution (17%; p < 0.05 and 14% n.s.) after 4 and 8 mg/kg verapamil, respectively. The clearance was reduced to 75% (n.s.) and 67% (p < 0.05) of the control value; changes were not dose-dependent.

KW - Pharmacokinetics

KW - Phenytoin

KW - Rat

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=0027953640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027953640&partnerID=8YFLogxK

U2 - 10.1016/0378-5173(94)90065-5

DO - 10.1016/0378-5173(94)90065-5

M3 - Article

AN - SCOPUS:0027953640

VL - 102

SP - 267

EP - 269

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-3

ER -

Access to Document

10.1016/0378-5173(94)90065-5